{"trialResultsOutput": {"Filters": {"@total": "37", "Filter": [{"@total": "14", "@label": "Trial Indications Adverse", "@name": "trialIndicationsAdverse", "FilterOption": [{"@id": "148", "@count": "3", "@label": "Headache"}, {"@id": "829", "@count": "2", "@label": "Fatigue"}, {"@id": "129", "@count": "2", "@label": "Gastrointestinal disease"}, {"@id": "415", "@count": "2", "@label": "Respiratory disorder"}, {"@id": "25", "@count": "1", "@label": "Anxiety disorder"}, {"@id": "3050", "@count": "1", "@label": "Chill"}, {"@id": "95", "@count": "1", "@label": "Dermatological disease"}, {"@id": "1833", "@count": "1", "@label": "Fever"}, {"@id": "188", "@count": "1", "@label": "Inflammatory disease"}, {"@id": "784", "@count": "1", "@label": "Lymphadenopathy"}, {"@id": "665", "@count": "1", "@label": "Mouth ulcer"}, {"@id": "226", "@count": "1", "@label": "Nausea"}, {"@id": "1991", "@count": "1", "@label": "Neutropenia"}, {"@id": "812", "@count": "1", "@label": "Tremor"}]}, {"@total": "16", "@label": "Trial Actions Secondary Interventions Primary", "@name": "trialActionsSecondaryInterventionsPrimary", "FilterOption": [{"@id": "991", "@count": "10", "@label": "Antiviral"}, {"@id": "12378", "@count": "6", "@label": "Prophylactic vaccine"}, {"@id": "1545", "@count": "4", "@label": "Anticancer"}, {"@id": "659", "@count": "4", "@label": "Coagulation inhibitor"}, {"@id": "166", "@count": "4", "@label": "Fibrinolysis stimulator"}, {"@id": "12370", "@count": "4", "@label": "Recombinant viral vector vaccine"}, {"@id": "7294", "@count": "3", "@label": "Antisense oligonucleotide inhibitor"}, {"@id": "1879", "@count": "3", "@label": "DNA vaccine"}, {"@id": "26035", "@count": "2", "@label": "siRNA agent"}, {"@id": "59620", "@count": "2", "@label": "Unspecified drug target"}, {"@id": "2953", "@count": "1", "@label": "Anti-inflammatory"}, {"@id": "2657", "@count": "1", "@label": "Antihypertensive"}, {"@id": "1596", "@count": "1", "@label": "Immunomodulator"}, {"@id": "12376", "@count": "1", "@label": "Nucleic acid vaccine"}, {"@id": "12372", "@count": "1", "@label": "Protein subunit vaccine"}, {"@id": "7292", "@count": "1", "@label": "Vulnerary agent"}]}, {"@total": "10", "@label": "Biomarker", "@name": "trialBiomarkerNames", "FilterOption": [{"@id": "1857", "@count": "2", "@label": "T-cell surface glycoprotein CD4"}, {"@id": "3447", "@count": "2", "@label": "T-cell surface glycoprotein CD8 alpha chain"}, {"@id": "1211", "@count": "1", "@label": "Alanine transaminase"}, {"@id": "28899", "@count": "1", "@label": "Alkaline phosphatase"}, {"@id": "2527", "@count": "1", "@label": "Aspartate aminotransferase"}, {"@id": "213", "@count": "1", "@label": "Creatinine"}, {"@id": "1236", "@count": "1", "@label": "Hemoglobin"}, {"@id": "252", "@count": "1", "@label": "Interferon gamma"}, {"@id": "812", "@count": "1", "@label": "Interleukin-2"}, {"@id": "11580", "@count": "1", "@label": "T-lymphocytes"}]}, {"@total": "11", "@label": "Indications", "@name": "indications", "FilterOption": [{"@id": "1049", "@count": "10", "@label": "Ebola virus infection"}, {"@id": "1076", "@count": "5", "@label": "Thrombosis"}, {"@id": "23", "@count": "4", "@label": "Angina"}, {"@id": "651", "@count": "4", "@label": "Cancer"}, {"@id": "57", "@count": "4", "@label": "Cardiovascular disease"}, {"@id": "574", "@count": "4", "@label": "Deep vein thrombosis"}, {"@id": "1048", "@count": "4", "@label": "Marburg virus infection"}, {"@id": "1584", "@count": "4", "@label": "Unstable angina"}, {"@id": "224", "@count": "3", "@label": "Myocardial infarction"}, {"@id": "114", "@count": "1", "@label": "Sepsis"}, {"@id": "52", "@count": "1", "@label": "Skin burns"}]}, {"@total": "11", "@label": "Trial Indications Pioneer", "@name": "trialIndicationsPioneer", "FilterOption": [{"@id": "1049", "@count": "7", "@label": "Ebola virus infection"}, {"@id": "1048", "@count": "4", "@label": "Marburg virus infection"}, {"@id": "1076", "@count": "2", "@label": "Thrombosis"}, {"@id": "23", "@count": "1", "@label": "Angina"}, {"@id": "651", "@count": "1", "@label": "Cancer"}, {"@id": "57", "@count": "1", "@label": "Cardiovascular disease"}, {"@id": "574", "@count": "1", "@label": "Deep vein thrombosis"}, {"@id": "224", "@count": "1", "@label": "Myocardial infarction"}, {"@id": "114", "@count": "1", "@label": "Sepsis"}, {"@id": "52", "@count": "1", "@label": "Skin burns"}, {"@id": "1584", "@count": "1", "@label": "Unstable angina"}]}, {"@total": "16", "@label": "Trial Date Start By Month", "@name": "trialDateStartByMonth", "FilterOption": [{"@count": "1", "@label": "199610"}, {"@count": "1", "@label": "199704"}, {"@count": "1", "@label": "199805"}, {"@count": "1", "@label": "200112"}, {"@count": "1", "@label": "200212"}, {"@count": "1", "@label": "200310"}, {"@count": "1", "@label": "200609"}, {"@count": "1", "@label": "200801"}, {"@count": "1", "@label": "201002"}, {"@count": "1", "@label": "201004"}, {"@count": "1", "@label": "201005"}, {"@count": "1", "@label": "201105"}, {"@count": "1", "@label": "201110"}, {"@count": "1", "@label": "201201"}, {"@count": "1", "@label": "201208"}, {"@count": "1", "@label": "201401"}]}, {"@total": "12", "@label": "Trial Terms Design", "@name": "trialTermsDesign", "FilterOption": [{"@id": "SSTINV", "@count": "16", "@label": "Interventional"}, {"@id": "SIARND", "@count": "12", "@label": "Randomized"}, {"@id": "SIPTRE", "@count": "12", "@label": "Treatment"}, {"@id": "SICPLC", "@count": "11", "@label": "Placebo Control"}, {"@id": "SIMMBD", "@count": "9", "@label": "Multiple Blind"}, {"@id": "SISPRL", "@count": "9", "@label": "Parallel Assignment"}, {"@id": "SIPPRE", "@count": "4", "@label": "Prevention"}, {"@id": "SIMSBD", "@count": "3", "@label": "Single Blind"}, {"@id": "SISXOV", "@count": "1", "@label": "Crossover Assignment"}, {"@id": "SICNOC", "@count": "1", "@label": "No Control"}, {"@id": "SIANON", "@count": "1", "@label": "Non-Randomized"}, {"@id": "SIMOPN", "@count": "1", "@label": "Open Label"}]}, {"@total": "11", "@label": "Trial Interventions Primary Alone Name Display", "@name": "trialInterventionsPrimaryAloneNameDisplay", "FilterOption": [{"@id": "11906", "@count": "3", "@label": "rNAPc2"}, {"@id": "57948", "@count": "2", "@label": "AVI-7537"}, {"@id": "60185", "@count": "2", "@label": "DNA vaccine (im, Marburg virus infection), NIH"}, {"@id": "57447", "@count": "2", "@label": "TKM-Ebola"}, {"@id": "13865", "@count": "1", "@label": "antithrombin alfa"}, {"@id": "54284", "@count": "1", "@label": "AVI-7288"}, {"@id": "39729", "@count": "1", "@label": "Ebola virus vaccine (recombinant adenoviral vector vaccine), Crucell/NIAID"}, {"@id": "66234", "@count": "1", "@label": "Ebola/Marburg vaccine (AdVac, PER.C6), Crucell/NIAID"}, {"@id": "66572", "@count": "1", "@label": "nucleic acid vaccine (Ebola virus infection), NIAID"}, {"@id": "62017", "@count": "1", "@label": "rVSVIN HIV-1 gag vaccine, Profectus Biosciences"}, {"@id": "47685", "@count": "1", "@label": "VRC-EBODNA012-00-VP"}]}, {"@total": "11", "@label": "Interventions", "@name": "trialInterventions", "FilterOption": [{"@id": "11906", "@count": "4", "@label": "rNAPc2"}, {"@id": "57948", "@count": "2", "@label": "AVI-7537"}, {"@id": "60185", "@count": "2", "@label": "DNA vaccine (im, Marburg virus infection), NIH"}, {"@id": "57447", "@count": "2", "@label": "TKM-Ebola"}, {"@id": "13865", "@count": "1", "@label": "antithrombin alfa"}, {"@id": "54284", "@count": "1", "@label": "AVI-7288"}, {"@id": "39729", "@count": "1", "@label": "Ebola virus vaccine (recombinant adenoviral vector vaccine), Crucell/NIAID"}, {"@id": "66234", "@count": "1", "@label": "Ebola/Marburg vaccine (AdVac, PER.C6), Crucell/NIAID"}, {"@id": "66572", "@count": "1", "@label": "nucleic acid vaccine (Ebola virus infection), NIAID"}, {"@id": "62017", "@count": "1", "@label": "rVSVIN HIV-1 gag vaccine, Profectus Biosciences"}, {"@id": "47685", "@count": "1", "@label": "VRC-EBODNA012-00-VP"}]}, {"@total": "8", "@label": "Sponsors/Collaborators", "@name": "trialCompanies", "FilterOption": [{"@id": "20520", "@count": "6", "@label": "National Institute of Allergy and Infectious Diseases"}, {"@id": "1041243", "@count": "5", "@label": "US Department of Defense"}, {"@id": "15546", "@count": "4", "@label": "Dendreon San Diego LLC"}, {"@id": "20518", "@count": "3", "@label": "National Institutes of Health"}, {"@id": "14240", "@count": "3", "@label": "Sarepta Therapeutics Inc"}, {"@id": "1032153", "@count": "2", "@label": "Tekmira Pharmaceuticals Corp"}, {"@id": "17254", "@count": "1", "@label": "Crucell NV"}, {"@id": "1041849", "@count": "1", "@label": "Guys Drug Research Unit"}]}, {"@total": "10", "@label": "Trial Date End By Month", "@name": "trialDateEndByMonth", "FilterOption": [{"@count": "1", "@label": "200708"}, {"@count": "1", "@label": "200905"}, {"@count": "1", "@label": "201004"}, {"@count": "1", "@label": "201006"}, {"@count": "1", "@label": "201111"}, {"@count": "1", "@label": "201112"}, {"@count": "1", "@label": "201204"}, {"@count": "1", "@label": "201208"}, {"@count": "1", "@label": "201301"}, {"@count": "1", "@label": "201407"}]}, {"@total": "6", "@label": "Trial Company Sponsor", "@name": "trialCompaniesSponsor", "FilterOption": [{"@id": "20520", "@count": "5", "@label": "National Institute of Allergy and Infectious Diseases"}, {"@id": "15546", "@count": "4", "@label": "Dendreon San Diego LLC"}, {"@id": "14240", "@count": "3", "@label": "Sarepta Therapeutics Inc"}, {"@id": "1032153", "@count": "2", "@label": "Tekmira Pharmaceuticals Corp"}, {"@id": "17254", "@count": "1", "@label": "Crucell NV"}, {"@id": "1041849", "@count": "1", "@label": "Guys Drug Research Unit"}]}, {"@total": "5", "@label": "Trial Patient Selection", "@name": "trialTermsPatientSelection", "FilterOption": [{"@id": "EAYAD", "@count": "11", "@label": "Young Adults"}, {"@id": "EAMAA", "@count": "9", "@label": "Middle-aged Adults"}, {"@id": "EVHVA", "@count": "8", "@label": "Healthy volunteers accepted"}, {"@id": "EVHVO", "@count": "6", "@label": "Healthy volunteers only"}, {"@id": "EGMAL", "@count": "3", "@label": "Male"}]}, {"@total": "4", "@label": "Trial Actions Primary Interventions Primary", "@name": "trialActionsPrimaryInterventionsPrimary", "FilterOption": [{"@id": "114", "@count": "4", "@label": "Factor VII antagonist"}, {"@id": "62405", "@count": "3", "@label": "VP24 gene inhibitor"}, {"@id": "75", "@count": "1", "@label": "Antithrombin III"}, {"@id": "12393", "@count": "1", "@label": "HIV GAG protein modulator"}]}, {"@total": "3", "@label": "Trial Source", "@name": "trialSources", "FilterOption": [{"@id": "CTGOVOTHERS", "@count": "6", "@label": "ClinicalTrials.gov and others"}, {"@id": "OTHERS", "@count": "6", "@label": "Others only"}, {"@id": "CTGOV", "@count": "4", "@label": "ClinicalTrials.gov only"}]}, {"@total": "4", "@label": "Trial Recruitment Status", "@name": "trialRecruitmentStatus", "FilterOption": [{"@id": "4", "@count": "10", "@label": "Completed"}, {"@id": "12", "@count": "3", "@label": "Status not specified"}, {"@id": "2", "@count": "2", "@label": "Recruiting"}, {"@id": "6", "@count": "1", "@label": "Terminated"}]}, {"@total": "3", "@label": "Trial Interventions Primary In Regimen Name Display", "@name": "trialInterventionsPrimaryInRegimenNameDisplay", "FilterOption": [{"@id": "60185", "@count": "1", "@label": "DNA vaccine (im, Marburg virus infection), NIH"}, {"@id": "66572", "@count": "1", "@label": "nucleic acid vaccine (Ebola virus infection), NIAID"}, {"@id": "11906", "@count": "1", "@label": "rNAPc2"}]}, {"@total": "3", "@label": "Trial Company Collaborator", "@name": "trialCompaniesCollaborator", "FilterOption": [{"@id": "1041243", "@count": "5", "@label": "US Department of Defense"}, {"@id": "20518", "@count": "3", "@label": "National Institutes of Health"}, {"@id": "20520", "@count": "1", "@label": "National Institute of Allergy and Infectious Diseases"}]}, {"@total": "4", "@label": "Trial Terms Endpoint", "@name": "trialTermsEndpoint", "FilterOption": [{"@id": "SIESFT", "@count": "15", "@label": "Safety"}, {"@id": "SIEEFC", "@count": "9", "@label": "Efficacy"}, {"@id": "SIEPCK", "@count": "8", "@label": "Pharmacokinetics"}, {"@id": "SIEPCD", "@count": "1", "@label": "Pharmacodynamics"}]}, {"@total": "3", "@label": "Trial Country", "@name": "trialCountries", "FilterOption": [{"@id": "US", "@count": "10", "@label": "US"}, {"@id": "GB", "@count": "2", "@label": "UK"}, {"@id": "UG", "@count": "1", "@label": "Uganda"}]}, {"@total": "3", "@label": "Trial Region", "@name": "trialRegions", "FilterOption": [{"@id": "USCA", "@count": "10", "@label": "US & Canada"}, {"@id": "NSWE", "@count": "2", "@label": "Northern, Southern & Western Europe"}, {"@id": "CSAF", "@count": "1", "@label": "Central & Southern Africa"}]}, {"@total": "2", "@label": "Trial Commercially Significant", "@name": "trialIsCommerciallySignificant", "FilterOption": [{"@id": "NO", "@count": "10", "@label": "No"}, {"@id": "YES", "@count": "6", "@label": "Yes"}]}, {"@total": "2", "@label": "Trial Outcome Available", "@name": "trialOutcomesAvailable", "FilterOption": [{"@id": "YES", "@count": "11", "@label": "Yes"}, {"@id": "NO", "@count": "5", "@label": "No"}]}, {"@total": "3", "@label": "Trial Phase", "@name": "trialPhase", "FilterOption": [{"@id": "C1", "@count": "14", "@label": "Phase 1 Clinical"}, {"@id": "C1A", "@count": "1", "@label": "Phase 1a Clinical"}, {"@id": "C1B", "@count": "1", "@label": "Phase 1b Clinical"}]}, {"@total": "41", "@label": "Exclusion Criteria Index", "@name": "trialExclusionCriteriaIndex", "FilterOption": [{"@id": "6836", "@count": "1", "@label": "HIV infection - Subjects with Psychiatric Disorders - Subjects with depression"}, {"@id": "6834", "@count": "1", "@label": "HIV infection - Subjects with Psychiatric Disorders"}, {"@id": "13999", "@count": "1", "@label": "HIV Vaccine - Subjects on Other Local/Systemic Therapy - Blood/blood products/immunoglobulins"}, {"@id": "14000", "@count": "1", "@label": "HIV Vaccine - Subjects on Other Local/Systemic Therapy - Immunosuppressants"}, {"@id": "13998", "@count": "1", "@label": "HIV Vaccine - Subjects on Other Local/Systemic Therapy"}, {"@id": "13987", "@count": "1", "@label": "HIV Vaccine - Subjects with CNS Disorders"}, {"@id": "13986", "@count": "1", "@label": "HIV Vaccine - Subjects with Cardiovascular Disorders"}, {"@id": "14003", "@count": "1", "@label": "HIV Vaccine - Subjects with Contraindications to Vaccine/Vaccine Ingredients"}, {"@id": "13992", "@count": "1", "@label": "HIV Vaccine - Subjects with Hematological Disorders"}, {"@id": "13990", "@count": "1", "@label": "HIV Vaccine - Subjects with Hepatobiliary Disorders"}, {"@id": "13995", "@count": "1", "@label": "HIV Vaccine - Subjects with Immunodeficiency/Autoimmune Disorders"}, {"@id": "13993", "@count": "1", "@label": "HIV Vaccine - Subjects with Malignancy"}, {"@id": "13985", "@count": "1", "@label": "HIV Vaccine - Subjects with Other Infectious Diseases - Subjects with hepatitis virus infection"}, {"@id": "13984", "@count": "1", "@label": "HIV Vaccine - Subjects with Other Infectious Diseases"}, {"@id": "13994", "@count": "1", "@label": "HIV Vaccine - Subjects with Other Systemic Disorders"}, {"@id": "13996", "@count": "1", "@label": "HIV Vaccine - Subjects with Prior HIV Vaccination"}, {"@id": "13997", "@count": "1", "@label": "HIV Vaccine - Subjects with Prior Other Vaccination"}, {"@id": "14004", "@count": "1", "@label": "HIV Vaccine - Subjects with Protocol Specified Laboratory Values"}, {"@id": "13988", "@count": "1", "@label": "HIV Vaccine - Subjects with Psychiatric Disorders"}, {"@id": "13989", "@count": "1", "@label": "HIV Vaccine - Subjects with Respiratory Disorders"}, {"@id": "6859", "@count": "1", "@label": "HIV infection - Pregnant or Breast Feeding Subjects"}, {"@id": "6893", "@count": "1", "@label": "HIV infection - Subjects on Other Local/Systemic Therapy - Subjects on antibacterial drugs"}, {"@id": "6963", "@count": "1", "@label": "HIV infection - Subjects on Other Local/Systemic Therapy - Subjects on immunomodulators"}, {"@id": "6892", "@count": "1", "@label": "HIV infection - Subjects on Other Local/Systemic Therapy"}, {"@id": "6832", "@count": "1", "@label": "HIV infection - Subjects with CNS Disorders - Subjects with seizure disorder"}, {"@id": "6829", "@count": "1", "@label": "HIV infection - Subjects with CNS Disorders"}, {"@id": "6828", "@count": "1", "@label": "HIV infection - Subjects with Cardiovascular Disorders - Subjects with hypertension"}, {"@id": "7809", "@count": "1", "@label": "HIV infection - Subjects with Hypersensitivity/Contraindications to Medications - Hypersensitivity/contraindications to vaccines"}, {"@id": "6850", "@count": "1", "@label": "HIV infection - Subjects with Malignancy"}, {"@id": "6945", "@count": "1", "@label": "HIV infection - Subjects with Metabolic/Endocrine Disorders - Subjects with diabetes mellitus"}, {"@id": "6946", "@count": "1", "@label": "HIV infection - Subjects with Metabolic/Endocrine Disorders - Subjects with thyroid dysfunction"}, {"@id": "6954", "@count": "1", "@label": "HIV infection - Subjects with Opportunistic/Other Infections - Subjects with herpes infection"}, {"@id": "6820", "@count": "1", "@label": "HIV infection - Subjects with Opportunistic/Other Infections"}, {"@id": "6844", "@count": "1", "@label": "HIV infection - Subjects with Other Systemic Disorders - Subjects with hematological disorders"}, {"@id": "6961", "@count": "1", "@label": "HIV infection - Subjects with Other Systemic Disorders - Subjects with inflammatory disorders"}, {"@id": "6962", "@count": "1", "@label": "HIV infection - Subjects with Other Systemic Disorders - Subjects with other immunological disorders"}, {"@id": "6847", "@count": "1", "@label": "HIV infection - Subjects with Other Systemic Disorders - Subjects with pulmonary disorders"}, {"@id": "6843", "@count": "1", "@label": "HIV infection - Subjects with Other Systemic Disorders"}, {"@id": "6968", "@count": "1", "@label": "HIV infection - Subjects with Prior Vaccination - Subjects with prior HIV vaccination"}, {"@id": "6969", "@count": "1", "@label": "HIV infection - Subjects with Prior Vaccination - Subjects with prior other vaccination"}, {"@id": "6837", "@count": "1", "@label": "HIV infection - Subjects with Psychiatric Disorders - Subjects with bipolar disorders"}]}, {"@total": "1", "@label": "Registry Id", "@name": "trialRegistries", "FilterOption": {"@id": "1000", "@count": "10", "@label": "CT.gov"}}, {"@total": "1", "@label": "Trial Endpoint Achieved", "@name": "trialEndpointsAchieved", "FilterOption": {"@id": "UNSPECIFIED", "@count": "8", "@label": "Unspecified"}}, {"@total": "13", "@label": "Inclusion Criteria Index", "@name": "trialInclusionCriteriaIndex", "FilterOption": [{"@id": "22465", "@count": "1", "@label": "HIV infection - Healthy Subjects"}, {"@id": "5263", "@count": "1", "@label": "HIV infection - Subjects at Risk of Developing HIV Infection"}, {"@id": "5330", "@count": "1", "@label": "HIV infection - Subjects with Normal/Acceptable Other Laboratory Profile - Subjects with normal/acceptable blood chemistry"}, {"@id": "5329", "@count": "1", "@label": "HIV infection - Subjects with Normal/Acceptable Other Laboratory Profile - Subjects with normal/acceptable hematological tests"}, {"@id": "5331", "@count": "1", "@label": "HIV infection - Subjects with Normal/Acceptable Other Laboratory Profile - Subjects with normal/acceptable liver function tests"}, {"@id": "5332", "@count": "1", "@label": "HIV infection - Subjects with Normal/Acceptable Other Laboratory Profile - Subjects with normal/acceptable renal function tests"}, {"@id": "5328", "@count": "1", "@label": "HIV infection - Subjects with Normal/Acceptable Other Laboratory Profile"}, {"@id": "16645", "@count": "1", "@label": "HIV Vaccine - HIV Seronegative Subjects"}, {"@id": "16647", "@count": "1", "@label": "HIV Vaccine - Subjects at Risk of HIV Infection - Subjects at low risk of HIV infection"}, {"@id": "16668", "@count": "1", "@label": "HIV Vaccine - Subjects with Protocol Specified Laboratory Values - Subjects with protocol specified hematological tests"}, {"@id": "16666", "@count": "1", "@label": "HIV Vaccine - Subjects with Protocol Specified Laboratory Values - Subjects with protocol specified liver function tests"}, {"@id": "16667", "@count": "1", "@label": "HIV Vaccine - Subjects with Protocol Specified Laboratory Values - Subjects with protocol specified renal function tests"}, {"@id": "16665", "@count": "1", "@label": "HIV Vaccine - Subjects with Protocol Specified Laboratory Values"}]}, {"@total": "2", "@label": "Patient Segment Index", "@name": "trialPatientSegmentIndex", "FilterOption": [{"@id": "7061", "@count": "1", "@label": "HIV infection - Subjects at Risk of Developing HIV Infection"}, {"@id": "11087", "@count": "1", "@label": "HIV Vaccine - HIV Seronegative Subjects"}]}, {"@total": "20", "@label": "Endpoint Index", "@name": "trialEndpointIndex", "FilterOption": [{"@id": "17717", "@count": "1", "@label": "HIV Vaccine - Hematology/Blood Chemistry Assessments"}, {"@id": "17720", "@count": "1", "@label": "HIV Vaccine - Hematology/Blood Chemistry Assessments - Renal function tests"}, {"@id": "17719", "@count": "1", "@label": "HIV Vaccine - Hematology/Blood Chemistry Assessments - Liver function tests"}, {"@id": "17700", "@count": "1", "@label": "HIV Vaccine - Assessment of Safety and Tolerability - Treatment discontinuation"}, {"@id": "17699", "@count": "1", "@label": "HIV Vaccine - Assessment of Safety and Tolerability - Reactogenicity(local/systemic reactions)"}, {"@id": "17698", "@count": "1", "@label": "HIV Vaccine - Assessment of Safety and Tolerability - Adverse events/serious adverse events"}, {"@id": "17689", "@count": "1", "@label": "HIV Vaccine - Assessment of Cellular Immunity"}, {"@id": "17691", "@count": "1", "@label": "HIV Vaccine - Assessment of Cellular Immunity - Assessment of CD8 cell responses"}, {"@id": "17690", "@count": "1", "@label": "HIV Vaccine - Assessment of Cellular Immunity - Assessment of CD4 cell responses"}, {"@id": "17694", "@count": "1", "@label": "HIV Vaccine - Assessment of Antibody Responses"}, {"@id": "9241", "@count": "1", "@label": "HIV infection - Other Laboratory Assessments - Renal function assessments"}, {"@id": "9240", "@count": "1", "@label": "HIV infection - Other Laboratory Assessments - Liver function assessments"}, {"@id": "9239", "@count": "1", "@label": "HIV infection - Other Laboratory Assessments - Hematological assessments"}, {"@id": "9255", "@count": "1", "@label": "HIV infection - Assessment of Safety and Tolerability - Assessment of treatment discontinuation"}, {"@id": "9248", "@count": "1", "@label": "HIV infection - Assessment of Safety and Tolerability - Assessment of local/systemic reactions"}, {"@id": "9247", "@count": "1", "@label": "HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"}, {"@id": "9218", "@count": "1", "@label": "HIV infection - Assessment of Immune Response"}, {"@id": "9225", "@count": "1", "@label": "HIV infection - Assessment of Immune Response - Assessment of anti-body titers/antibody responses"}, {"@id": "9216", "@count": "1", "@label": "HIV infection - Assessment of CD8 Cell Responses"}, {"@id": "9214", "@count": "1", "@label": "HIV infection - Assessment of CD4 Cell Responses"}]}, {"@total": "0", "@label": "Trial Actions Primary Interventions Control", "@name": "trialActionsPrimaryInterventionsControl"}, {"@total": "0", "@label": "Trial Actions Secondary Interventions Control", "@name": "trialActionsSecondaryInterventionsControl"}, {"@total": "0", "@label": "Trial Interventions Control Alone Name Display", "@name": "trialInterventionsControlAloneNameDisplay"}, {"@total": "0", "@label": "Trial Interventions Control In Regimen Name Display", "@name": "trialInterventionsControlInRegimenNameDisplay"}, {"@total": "0", "@label": "Active Controls", "@name": "trialActiveControls"}, {"@total": "0", "@label": "Primary Completion Filter by Month", "@name": "trialPrimaryCompletionDateByMonth"}, {"@total": "0", "@label": "Funder Type", "@name": "trialFunderType"}]}, "SearchResults": {"Trial": [{"ActionsSecondaryInterventionsPrimary": {"Action": ["DNA vaccine", "Nucleic acid vaccine", "Prophylactic vaccine", "Recombinant viral vector vaccine"]}, "DateChangeLast": "2013-01-31T00:00:00Z", "Countries": {"Country": "Uganda"}, "Identifiers": {"Identifier": ["NCT00997607", "RV 247"]}, "TitleDisplay": "Evaluating an Ebola and a Margurg Vaccine in Uganda", "Indications": {"Indication": ["Ebola virus infection", "Marburg virus infection"]}, "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Prevention", "Randomized", "Multiple Blind", "Parallel Assignment"]}, "RecruitmentStatus": "Completed", "Teaser": "This study would test the experimental vaccines for the <b>Ebola</b> (VRC-EBODNA023-00-VP) and Marburg (VRC-MARDNA025-00-VP) viruses, first administered separately and then together, to...injection site.Pregnant, breast-feeding, or planning to become pregnant during the first 24 weeks after enrollmentHistory of <b>Ebola</b> or Marburg virus exposureOccupational health risk of exposure to the <b>Ebola</b> or Marburg virus known to be higher than that of the general populationHas received any of the following substances...", "DateEnd": "2012-04-30T00:00:00Z", "CompaniesSponsor": {"Company": "National Institute of Allergy and Infectious Diseases"}, "PatientCountEnrollment": 108, "Phase": "Phase 1b Clinical", "InterventionsPrimaryDisplay": {"Intervention": ["DNA vaccine (im, Marburg virus infection), NIH alone", "nucleic acid vaccine (Ebola virus infection), NIAID alone", "DNA vaccine (im, Marburg virus infection), NIH plus nucleic acid vaccine (Ebola virus infection), NIAID"]}, "DateStart": "2010-02-28T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers accepted", "Young Adults", "Middle-aged Adults"]}, "@Id": "61219", "BiomarkerNames": {"BiomarkerName": "T-lymphocytes"}, "TermsEndpoint": {"Term": ["Safety", "Efficacy"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["DNA vaccine", "Prophylactic vaccine"]}, "DateChangeLast": "2010-08-11T00:00:00Z", "CompaniesCollaborator": {"Company": "National Institutes of Health"}, "Countries": {"Country": "US"}, "Identifiers": {"Identifier": ["04-I-0028", "040028", "NCT00072605", "VRC-204"]}, "TitleDisplay": "Experimental ebola vaccine trial", "Indications": {"Indication": "Ebola virus infection"}, "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment", "Randomized", "Single Blind", "Placebo Control"]}, "RecruitmentStatus": "Completed", "Teaser": "...safety of an experimental vaccine (VRC-EBODNA012-00-VP) developed to protect against <b>Ebola</b> virus infection and to determine if the vaccine induces an immune response to the...Washington, DC. High rates of immune responses were observed at all dose levels. <b>Ebola</b>-specific antibody responses against at least one of the encoded antigens were detected...4000 for either GP antigen. Pseudotyped virus neutralization assay revealed that <b>Ebola</b> virus-specific neutralizing antibody was not detected in any subject. Of the two...", "DateEnd": "2007-08-31T00:00:00Z", "CompaniesSponsor": {"Company": "National Institute of Allergy and Infectious Diseases"}, "PatientCountEnrollment": 27, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "VRC-EBODNA012-00-VP alone"}, "DateStart": "2003-10-31T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers accepted", "Young Adults"]}, "@Id": "9023", "BiomarkerNames": {"BiomarkerName": ["T-cell surface glycoprotein CD4 ", " T-cell surface glycoprotein CD8 alpha chain"]}, "TermsEndpoint": {"Term": ["Safety", "Efficacy"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Prophylactic vaccine", "Recombinant viral vector vaccine"]}, "DateChangeLast": "2010-02-16T00:00:00Z", "CompaniesCollaborator": {"Company": "National Institutes of Health"}, "Countries": {"Country": "US"}, "Identifiers": {"Identifier": ["06-I-0237", "060237", "NCT00374309"]}, "TitleDisplay": "Experimental Vaccine for Prevention of Ebola Virus Infection", "Indications": {"Indication": "Ebola virus infection"}, "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Prevention", "Randomized", "Multiple Blind", "Placebo Control", "Parallel Assignment"]}, "RecruitmentStatus": "Completed", "Teaser": "...doses of 2 x 10(9), 2 x 10(10) and 2 x 10(11) virus particles (vp) by im injection. Secondary endpoints would be indicated by <b>Ebola</b>-specific antibody and cellular immune responses at weeks 0, 4 and 24 and Ad5 antibody titer at weeks 0, 4, and 24. Exploratory...serotype 5 antibody titers (Ad5 Ab) upto week 4. It was hypothesized that this vaccine would be safe and elicit immune responses to <b>Ebola</b>. Exploratory evaluations included immunogenicity evaluations at weeks 12, 24, and 48 and Ad5 Ab titers at week 24 and 48. A...", "DateEnd": "2009-05-31T00:00:00Z", "CompaniesSponsor": {"Company": "National Institute of Allergy and Infectious Diseases"}, "PatientCountEnrollment": 48, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "Ebola virus vaccine (recombinant adenoviral vector vaccine), Crucell/NIAID alone"}, "DateStart": "2006-09-26T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers accepted", "Young Adults", "Middle-aged Adults"]}, "@Id": "9020", "TermsEndpoint": {"Term": ["Safety", "Efficacy"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["DNA vaccine", "Prophylactic vaccine"]}, "DateChangeLast": "2011-03-17T00:00:00Z", "CompaniesCollaborator": {"Company": "National Institutes of Health"}, "Countries": {"Country": "US"}, "Identifiers": {"Identifier": ["08-I-0065", "080065", "NCT00605514"]}, "TitleDisplay": "Ebola and Marburg Virus Vaccines", "Indications": {"Indication": ["Ebola virus infection", "Marburg virus infection"]}, "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Prevention", "Non-Randomized", "Open Label", "No Control", "Parallel Assignment"]}, "RecruitmentStatus": "Completed", "Teaser": "...subjects will receive the Marburg DNA vaccine and Group 2 subjects will receive the <b>Ebola</b> DNA WT vaccine. The first 3 enrollments in each group will occur no faster than one...Before the initiation of Group 2, the FDA must have assessed administration of the <b>Ebola</b> DNA WT vaccine as safe to proceed. In addition, there will be a study pause with...dose 4 mg and Day 56 plus or minus 7 with a dose 4 mg. VRC 206 Group 2 will receive <b>Ebola</b> DNA WT, accrue 10 subjects and deliver injections on Day 0 with a dose of 4 mg, Day...", "DateEnd": "2010-06-30T00:00:00Z", "CompaniesSponsor": {"Company": "National Institute of Allergy and Infectious Diseases"}, "PatientCountEnrollment": 20, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "DNA vaccine (im, Marburg virus infection), NIH alone"}, "DateStart": "2008-01-31T00:00:00Z", "TermsPatientSelection": {"Term": ["Young Adults", "Middle-aged Adults"]}, "@Id": "11465", "TermsEndpoint": {"Term": ["Safety", "Efficacy"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Prophylactic vaccine", "Recombinant viral vector vaccine"]}, "DateChangeLast": "2012-01-20T00:00:00Z", "CompaniesCollaborator": {"Company": "National Institute of Allergy and Infectious Diseases"}, "DateStart": "2010-04-06T00:00:00Z", "TitleDisplay": "A phase I, safety and immunogencity study of an Ebola/Marburg virus vaccine", "Indications": {"Indication": ["Ebola virus infection", "Marburg virus infection"]}, "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment"]}, "RecruitmentStatus": "Completed", "Teaser": "The vaccine was found to be safe and immunogenic [1092813]. This was a phase I, safety and immunogencity study of an <b>Ebola</b>/Marburg virus vaccine [1092813]. By April 2010, the trial had been completed [1092813].", "DateEnd": "2010-04-06T00:00:00Z", "CompaniesSponsor": {"Company": "Crucell NV"}, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "Ebola/Marburg vaccine (AdVac, PER.C6), Crucell/NIAID alone"}, "@Id": "65870", "TermsEndpoint": {"Term": ["Safety", "Efficacy"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Antisense oligonucleotide inhibitor", "Antiviral"]}, "DateChangeLast": "2012-07-13T00:00:00Z", "Identifiers": {"Identifier": ["6002-us-101", "NCT01353027"]}, "CompaniesCollaborator": {"Company": "US Department of Defense"}, "Countries": {"Country": "US"}, "ActionsPrimaryInterventionsPrimary": {"Action": "VP24 gene inhibitor"}, "TitleDisplay": "Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus", "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment", "Randomized", "Multiple Blind", "Placebo Control", "Parallel Assignment"]}, "RecruitmentStatus": "Completed", "Teaser": "...total elimination and 30.7 of AVI-7539 elimination [1274750], [1276835]. The purpose of this study was to characterize the safety, tolerability and pharmacokinetics of single administration of AVI-6002, a post-exposure prophylaxis candidate treatment for <b>Ebola</b> virus, in healthy human subjects.In October 2011, an independent data and safety monitoring board (DSMB) recommended the study progress to the next highest dosing level after no safety concerns were identified from five cohorts [1232439].In February 2012...", "IndicationsAdverse": {"Indication": ["Dermatological disease", "Fatigue", "Gastrointestinal disease", "Headache", "Nausea", "Respiratory disorder"]}, "DateEnd": "2011-11-30T00:00:00Z", "CompaniesSponsor": {"Company": "Sarepta Therapeutics Inc"}, "PatientCountEnrollment": 30, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "AVI-7537 alone"}, "DateStart": "2010-05-31T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers only", "Young Adults", "Middle-aged Adults"]}, "@Id": "77351", "TermsEndpoint": {"Term": ["Safety", "Pharmacokinetics"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Anticancer", "Antiviral", "Coagulation inhibitor", "Fibrinolysis stimulator"]}, "DateChangeLast": "2009-05-19T00:00:00Z", "Countries": {"Country": "UK"}, "ActionsPrimaryInterventionsPrimary": {"Action": "Factor VII antagonist"}, "TitleDisplay": "A phase Ia, single-center, double-blind, randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of rNAPc2 in healthy male volunteers", "Indications": {"Indication": ["Angina", "Cancer", "Cardiovascular disease", "Deep vein thrombosis", "Ebola virus infection", "Myocardial infarction", "Thrombosis", "Unstable angina"]}, "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment", "Randomized", "Multiple Blind", "Placebo Control"]}, "RecruitmentStatus": "Completed", "Teaser": "This phase Ia, single-center, double-blind, randomized, placebo-controlled study was designed to evaluate the safety, pharmacokinetics and efficacy of rNAPc2 in healthy male volunteers [266827], [264179].", "CompaniesSponsor": {"Company": "Dendreon San Diego LLC"}, "PatientCountEnrollment": 30, "Phase": "Phase 1a Clinical", "InterventionsPrimaryDisplay": {"Intervention": "rNAPc2 alone"}, "DateStart": "1997-04-30T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers accepted", "Male"]}, "@Id": "55425", "TermsEndpoint": {"Term": ["Safety", "Efficacy", "Pharmacokinetics"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Anti-inflammatory", "Antihypertensive", "Antiviral", "Vulnerary agent"]}, "DateChangeLast": "2010-09-21T00:00:00Z", "Countries": {"Country": "UK"}, "ActionsPrimaryInterventionsPrimary": {"Action": "Antithrombin III"}, "TitleDisplay": "A phase I, safety study of AT-III in healthy male volunteers", "Indications": {"Indication": ["Ebola virus infection", "Marburg virus infection", "Sepsis", "Skin burns", "Thrombosis"]}, "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment"]}, "RecruitmentStatus": "Status not specified", "Teaser": "A phase I, safety study of AT-III in healthy male volunteers [223347], [227738].", "CompaniesSponsor": {"Company": "Guys Drug Research Unit"}, "PatientCountEnrollment": 20, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "antithrombin alfa alone"}, "DateStart": "1996-10-21T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers accepted", "Male", "Young Adults"]}, "@Id": "52666", "TermsEndpoint": {"Term": "Safety"}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Antiviral", "Unspecified drug target", "siRNA agent"]}, "DateChangeLast": "2014-03-10T00:00:00Z", "CompaniesCollaborator": {"Company": "US Department of Defense"}, "Countries": {"Country": "US"}, "Identifiers": {"Identifier": ["NCT01518881", "TKM-EBOV-001"]}, "TitleDisplay": "Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion", "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment", "Randomized", "Single Blind", "Placebo Control", "Parallel Assignment"]}, "RecruitmentStatus": "Recruiting", "Teaser": "...would have up to six cohorts with four subjects (three receiving TKM-100201 [TKM-<b>Ebola</b>] and one receiving saline placebo) in each cohort. Additional cohorts might be enrolled...the study would have up to three cohorts with four subjects (three receiving TKM-<b>Ebola</b> and one receiving saline placebo) in each cohort. Additional cohorts might be enrolled...within 30 days of screening (as determined by the investigator[s])Reports a history of <b>Ebola</b> virus exposureReports an occupational health risk of exposure to <b>Ebola</b> virus known...", "DateEnd": "2012-08-31T00:00:00Z", "CompaniesSponsor": {"Company": "Tekmira Pharmaceuticals Corp"}, "PatientCountEnrollment": 24, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "TKM-Ebola alone"}, "DateStart": "2012-01-31T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers only", "Young Adults", "Middle-aged Adults"]}, "@Id": "84326", "TermsEndpoint": {"Term": ["Safety", "Pharmacokinetics"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Antiviral", "Unspecified drug target", "siRNA agent"]}, "DateChangeLast": "2014-01-30T00:00:00Z", "CompaniesCollaborator": {"Company": "US Department of Defense"}, "Countries": {"Country": "US"}, "Identifiers": {"Identifier": ["NCT02041715", "TKM-EBOV-002"]}, "TitleDisplay": "Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous TKM-100802", "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment", "Randomized", "Single Blind", "Placebo Control", "Parallel Assignment"]}, "RecruitmentStatus": "Recruiting", "Teaser": "...demonstrates a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibodyReports infections requiring antibiotic therapy within 28 days of screening (as determined by the PI)Reports a history of <b>Ebola</b> virus exposureReports an occupational health risk of exposure to <b>Ebola</b> virus known to be higher than that of the general populationReports a known or suspected hypersensitivity or previous severe reactions to any of the constituents of the TKM-100802 including oligonucleotide- or lipid-based...", "DateEnd": "2014-07-31T00:00:00Z", "CompaniesSponsor": {"Company": "Tekmira Pharmaceuticals Corp"}, "PatientCountEnrollment": 28, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "TKM-Ebola alone"}, "DateStart": "2014-01-31T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers only", "Young Adults", "Middle-aged Adults"]}, "@Id": "168906", "TermsEndpoint": {"Term": ["Safety", "Pharmacokinetics"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Anticancer", "Antiviral", "Coagulation inhibitor", "Fibrinolysis stimulator"]}, "DateChangeLast": "2009-05-19T00:00:00Z", "DateStart": "2001-12-31T00:00:00Z", "ActionsPrimaryInterventionsPrimary": {"Action": "Factor VII antagonist"}, "TitleDisplay": "A phase I, randomized, placebo-controlled, double-blind, multiple-period crossover study to investigate the potential of recombinant factor VIIa (rVIIa) to induce thrombin generation in healthy subjects pretreated with rNAPc2", "Indications": {"Indication": ["Angina", "Cancer", "Cardiovascular disease", "Deep vein thrombosis", "Ebola virus infection", "Myocardial infarction", "Thrombosis", "Unstable angina"]}, "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment", "Randomized", "Multiple Blind", "Placebo Control", "Crossover Assignment"]}, "RecruitmentStatus": "Status not specified", "Teaser": "This phase I, randomized, placebo-controlled, double-blind, multiple-period crossover study was designed to investigate the potential of recombinant factor VIIa (rVIIa) to induce thrombin generation in healthy subjects pretreated with rNAPc2 [492192], [492284].", "CompaniesSponsor": {"Company": "Dendreon San Diego LLC"}, "PatientCountEnrollment": 6, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "rNAPc2 plus rVIIa"}, "TermsPatientSelection": {"Term": "Healthy volunteers accepted"}, "@Id": "55458", "TermsEndpoint": {"Term": "Efficacy"}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Anticancer", "Antiviral", "Coagulation inhibitor", "Fibrinolysis stimulator"]}, "DateChangeLast": "2009-05-19T00:00:00Z", "DateStart": "2002-12-31T00:00:00Z", "ActionsPrimaryInterventionsPrimary": {"Action": "Factor VII antagonist"}, "TitleDisplay": "A phase I study to evaluate the safety, pharmacodynamics and pharmacokinetics of rNAPc2 in healthy volunteers", "Indications": {"Indication": ["Angina", "Cancer", "Cardiovascular disease", "Deep vein thrombosis", "Ebola virus infection", "Thrombosis", "Unstable angina"]}, "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment"]}, "RecruitmentStatus": "Status not specified", "Teaser": "This phase I study was designed to evaluate the safety, pharmacodynamics and pharmacokinetics of rNAPc2 in healthy volunteers [473059].", "CompaniesSponsor": {"Company": "Dendreon San Diego LLC"}, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "rNAPc2 alone"}, "TermsPatientSelection": {"Term": "Healthy volunteers accepted"}, "@Id": "55450", "TermsEndpoint": {"Term": ["Safety", "Pharmacokinetics", "Pharmacodynamics"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Anticancer", "Antiviral", "Coagulation inhibitor", "Fibrinolysis stimulator"]}, "DateChangeLast": "2009-05-19T00:00:00Z", "Countries": {"Country": "US"}, "ActionsPrimaryInterventionsPrimary": {"Action": "Factor VII antagonist"}, "TitleDisplay": "A phase I, randomized, dose-escalation, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of rNAPc2 in healthy male volunteers", "Indications": {"Indication": ["Angina", "Cancer", "Cardiovascular disease", "Deep vein thrombosis", "Ebola virus infection", "Myocardial infarction", "Thrombosis", "Unstable angina"]}, "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment", "Randomized", "Multiple Blind", "Placebo Control"]}, "RecruitmentStatus": "Completed", "Teaser": "This phase I, randomized, dose-escalation, double-blind, placebo-controlled study was designed to evaluate the safety, pharmacokinetics and efficacy of rNAPc2 in healthy male volunteers [287149], [317563].", "CompaniesSponsor": {"Company": "Dendreon San Diego LLC"}, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "rNAPc2 alone"}, "DateStart": "1998-05-13T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers accepted", "Male"]}, "@Id": "55444", "TermsEndpoint": {"Term": ["Safety", "Efficacy", "Pharmacokinetics"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Antisense oligonucleotide inhibitor", "Antiviral"]}, "DateChangeLast": "2013-01-25T00:00:00Z", "Identifiers": {"Identifier": ["7537-us-101", "NCT01593072", "W9113M-10-C-0056"]}, "CompaniesCollaborator": {"Company": "US Department of Defense"}, "Countries": {"Country": "US"}, "ActionsPrimaryInterventionsPrimary": {"Action": "VP24 gene inhibitor"}, "TitleDisplay": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers", "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment", "Randomized", "Multiple Blind", "Placebo Control", "Parallel Assignment"]}, "RecruitmentStatus": "Terminated", "Teaser": "The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of AVI-7537 compared to matched placebo in healthy male and female subjects.", "DateEnd": "2013-01-31T00:00:00Z", "CompaniesSponsor": {"Company": "Sarepta Therapeutics Inc"}, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "AVI-7537 alone"}, "DateStart": "2012-08-31T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers only", "Young Adults", "Middle-aged Adults"]}, "@Id": "87199", "TermsEndpoint": {"Term": ["Safety", "Pharmacokinetics"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Immunomodulator", "Prophylactic vaccine", "Protein subunit vaccine", "Recombinant viral vector vaccine"]}, "DateChangeLast": "2013-12-02T00:00:00Z", "Identifiers": {"Identifier": [11669, "HVTN 090", "NCT01438606"]}, "Countries": {"Country": "US"}, "PatientSegmentTerms": {"PatientSegment": ["HIV Vaccine - HIV Seronegative Subjects", "HIV infection - Subjects at Risk of Developing HIV Infection"]}, "ActionsPrimaryInterventionsPrimary": {"Action": "HIV GAG protein modulator"}, "TitleDisplay": "Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults", "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Prevention", "Randomized", "Multiple Blind", "Placebo Control", "Parallel Assignment"]}, "RecruitmentStatus": "Completed", "Teaser": "The purpose of this placebo-controlled, dose-escalation study was to evaluate the safety and immune response to a rVSVIN HIV-1 gag vaccine in HIV-uninfected subjects. Study researchers would also determine the maximum dose of the vaccine that participants can safely receive.By December 2011, 20 subjects had been immunized [1252290].By May 2012, 51 subjects had been vaccinated without any safety concerns [1286555].By September 2013, study was completed [1480508].", "IndicationsAdverse": {"Indication": ["Chill", "Fever", "Headache", "Lymphadenopathy", "Mouth ulcer", "Neutropenia"]}, "CompaniesSponsor": {"Company": "National Institute of Allergy and Infectious Diseases"}, "PatientCountEnrollment": 60, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "rVSVIN HIV-1 gag vaccine, Profectus Biosciences alone"}, "DateStart": "2011-10-31T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers only", "Young Adults", "Middle-aged Adults"]}, "@Id": "81125", "BiomarkerNames": {"BiomarkerName": ["Alanine transaminase ", " Alkaline phosphatase ", " Aspartate aminotransferase ", " Creatinine ", " Hemoglobin ", " Interferon gamma ", " Interleukin-2 ", " T-cell surface glycoprotein CD4 ", " T-cell surface glycoprotein CD8 alpha chain"]}, "TermsEndpoint": {"Term": ["Safety", "Efficacy"]}}, {"ActionsSecondaryInterventionsPrimary": {"Action": ["Antisense oligonucleotide inhibitor", "Antiviral"]}, "DateChangeLast": "2013-03-13T00:00:00Z", "Identifiers": {"Identifier": ["6003-us-101", "NCT01353040", "W9113M-10-C-0056"]}, "CompaniesCollaborator": {"Company": "US Department of Defense"}, "Countries": {"Country": "US"}, "ActionsPrimaryInterventionsPrimary": {"Action": "VP24 gene inhibitor"}, "TitleDisplay": "Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Marburg Virus", "PrimaryCompletionDate": "", "TermsDesign": {"Term": ["Interventional", "Treatment", "Randomized", "Multiple Blind", "Placebo Control", "Parallel Assignment"]}, "RecruitmentStatus": "Completed", "Teaser": "The purpose of this study was to characterize the safety and pharmacology of single iv administration of AVI-6003 (PMOplus), a post-exposure prophylaxis candidate treatment for Marburg virus.In October 2011, independent Data and Safety Monitoring Board recommended the study to progress to the next highest dosing level (9 mg/kg) after no safety concerns were identified from five cohorts [1232439], [1232679], [1229947]. In October 2011, dosing of the first subject was started [1232679]. In February 2012, the DSMB suggested the study to progress to multiple ascending dose as no safety concerns were identified from six cohorts (n = 30) [1261544].", "IndicationsAdverse": {"Indication": ["Anxiety disorder", "Fatigue", "Gastrointestinal disease", "Headache", "Inflammatory disease", "Respiratory disorder", "Tremor"]}, "DateEnd": "2011-12-31T00:00:00Z", "CompaniesSponsor": {"Company": "Sarepta Therapeutics Inc"}, "PatientCountEnrollment": 30, "Phase": "Phase 1 Clinical", "InterventionsPrimaryDisplay": {"Intervention": "AVI-7288 alone"}, "DateStart": "2011-05-31T00:00:00Z", "TermsPatientSelection": {"Term": ["Healthy volunteers only", "Young Adults", "Middle-aged Adults"]}, "@Id": "77350", "TermsEndpoint": {"Term": ["Safety", "Pharmacokinetics"]}}]}, "@hits": "16", "@totalResults": "16", "@offset": "0"}}